Unlocking Alzheimer's: Biologics To Biosimilars- India's Healing Horizon

To address the growing need for complex medications, India must strategically shift toward biologics and biosimilars, utilizing its manufacturing capabilities in the face of a worldwide patent cliff. For conditions such as Alzheimer's, where biologics such as anti-amyloid antibodies show promising results, this shift promotes easy access. Bharat explores therapeutic potential through integrated therapeutics, encompassing traditional bioactives such as flavonoids like quercetin and curcumin, alongside biosimilars like donanemab, which have the ability to directly affect pathogenic events such as dysregulated gene expression, tau hyperphosphorylation, and amyloid formation. Moreover, since AD is a heterozygous disorder, biologics can provide a pathway to disease-modifying therapies that can be tailored to the genetic and molecular profile of a patient. This presents India (Bharat) as a pioneer in fusing traditional knowledge with cutting-edge biotechnology for comprehensive and cost-effective management of Alzheimer's disease.